Dr. Rafael Gonzalez has always been passionate about helping those suffering from degenerative disorders. He graduated from University of California, Irvine with his Ph.D in Anatomy and Neurobiology and has since been responsible for the development of clinical stem cell applications for several diseases and trauma states. He leads multiple investigational new drug applications with patented stem cell technology, works on the clinical development of immune-based therapies with natural killer cells, and has several publications to back his expertise. He also teaches worldwide for the American Academy of Antiaging on age related disorders and the role of the immune system and cell therapeutics to aid in maintaining health. Dr. Gonzalez is well respected in the regenerative medicine sector for his ability to understand all aspects of cell-based therapeutics and their clinical applicability.

Dr. Nguyen has more than 30 years in the field of biological sciences. He has spent over 20 years in academia with a focus on molecular biology, virology, biochemistry, and genetics, where he lectured undergraduate and graduate students as Principal Scientist at University of California, Irvine. For the past 11 years, Dr. Nguyen has been implementing a development program by leading all GLP and cGMP testing to include validation of our cell-based and their derivatives platform. He also leads our reference lab with many years of experience with in vitro cell testing. He has several publications in cell and molecular biology and biochemistry.

With over 45 years of experience in the biotechnology sector, Dr. Chelyapov has studied, researched, and developed various vaccines, molecular disease targets, nano delivery systems and cell-based technologies designed to target age related disorders. He has several publications and patents in all aspects of biology and is a pioneer in developing cell-based therapeutics for senescence. He is dedicated to helping age-related disorders through targeted removal of old cells, which may force a natural regenerative healing response. In his tenure with RESTEM, he has developed highly active NK cells along with an understanding of various extraordinary properties that these cells are capable of.

With her extensive experience in cell therapy and her master’s degree in Pharmacology, Tatiana is responsible for incredible breakthroughs at RESTEM. She has worked in the field for over 10 years conducting in-vivo and pre-clinical studies, as well as biological manufacturing. She has developed and validated new mouse tumor models to evaluate the efficacy of novel immunotherapy products, with many publications behind her. At RESTEM, Tatiana establishes innovative in-vitro methods to study engineered cell therapies, as well as conducts pharmacological evaluation of test agents in various in-vitro oncology models. In particular, she conducts revolutionary studies on natural killer cells for cell therapy.

Marisol Castro-Paiz has an impressive 25 years of experience in the biotechnology, pharmaceutical, and medical device industries behind her, as well as certifications in clinical trials administration from UCSD, project management from PMI, and quality assurance auditing from AQS. She graduated from Stanford University with a B.S. degree in Biological Sciences with Honors. As Director of Clinical, Regulatory, and Quality Systems for RESTEM, she directs and oversees Quality Control and Quality Assurance (QC/QA), contract lab manufacturing and testing in compliance with cGMP and with GTP for HCT/P, in-house cleanroom programs for aseptic processing, non-clinical safety testing, domestic and international regulatory affairs, clinical Phase 1 INDs and projects in collaboration with investigators and CROs for clinical data management and operations.